Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebraca Wafer + TMZ in Recurrent High-Grade Glioma
NCT03234595Phase 2Completed
- Sponsor
- Everfront Biotech Inc.
- Start
- Nov 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of EF-009 in glioblastoma (GBM), anaplastic astrocytoma (AA), sponsored by Everfront Biotech Inc.. Started Nov 2017; status: completed.
02
Drugs
EF-009
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT03234595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234595.